Company Overview and News

96
20 Stocks With Massive Post-Millennial Appeal

2018-09-19 investorplace - 1
If there’s one thing that’s more important than anything else in investing, it is this: look forward, not back. One way to keep your eye toward the future is by looking at what the kids are doing. While the youngest cohort of millennials and Generation Z, also known as post-millennials, don’t have money and therefore don’t impact the economy in any meaningful way, they will inevitably grow up and get jobs.
FB YUM UL UAA NFLX LB GOOG MDLZ K UA AMZN NKE AAPL KHC KO SBUX HSY MCD SNAP

17
Exclusive: Qualcomm prepares to add new board directors - sources

2018-09-18 channelnewsasia - 1
Qualcomm Inc is preparing to add at least two new directors to its board, people familiar with the matter told Reuters, as the U.S. smartphone chip maker looks to appease shareholders who withheld voting support for its board last March.
LRCX CCV AAL CMCSA BC94 SMSN CCZ MDLZ CCV.CL AVGO AAPL BRCM QCOM CMCSK SMSD

16
Exclusive: Qualcomm prepares to add new board directors - sources

2018-09-18 reuters
(Reuters) - Qualcomm Inc is preparing to add at least two new directors to its board, people familiar with the matter told Reuters, as the U.S. smartphone chip maker looks to appease shareholders who withheld voting support for its board last March.
LRCX CCV AAL CMCSA BC94 SMSN CCZ MDLZ CCV.CL AVGO AAPL BRCM QCOM CMCSK SMSD

2
Mondelēz International Named Again to the Dow Jones Sustainability Index

2018-09-13 globenewswire
DEERFIELD, Ill., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Mondelēz International has once again been named to the Dow Jones Sustainability Index (DJSI) for both the North America and World indices. The DJSI is a globally recognized independent benchmark that conducts comprehensive assessments of a company's economic, environmental and social performance with a strong focus on long-term value creation for shareholders.
MDLZ

2
Cadbury owner Mondelez stockpiling chocolate ahead of Brexit

2018-09-11 nzherald.co.nz
Hubert Weber, European chief of Mondelez International, says the company is stockpiling ingredients, chocolate and cookies as part of contingency plans for a disruptive "hard Brexit."
MDLZ

2
Cadbury owner Mondelez builds Brexit chocolate stash

2018-09-11 livemint
London: Cadbury owner Mondelez International is stockpiling ingredients, chocolates and biscuits in Britain to avoid interruptions to business in the event of a hard Brexit.
MDLZ

2
Cadbury owner Mondelez stockpiling chocolate ahead of Brexit

2018-09-11 nzherald.co.nz
LONDON (AP) — A major confectionery maker says Brexit could come between Britons and their beloved chocolate.
MDLZ

2
Cadbury owner Mondelez builds Brexit chocolate stash

2018-09-11 channelnewsasia
Cadbury owner Mondelez International is stockpiling ingredients, chocolates and biscuits in Britain to avoid interruptions to business in the event of a hard Brexit.
MDLZ

6
Report: Snack giant stockpiles biscuits for hard Brexit

2018-09-11 malaymail
LONDON, Sept 11 — Mondelez International, owner of British chocolate maker Cadbury, is stockpiling ingredients, confectionery and biscuits in the event of a no-deal Brexit, the US snack-food group’s European boss said today.
KHC MDLZ

2
Cadbury owner Mondelez stockpiles products, prepares for hard Brexit - the Times

2018-09-11 reuters
(Reuters) - Mondelez International Inc (MDLZ.O), the owner of Cadbury brand, is stockpiling ingredients, chocolates and biscuits in case of a no-deal Brexit, the Times reported bit.ly/2MjCYjJ on Tuesday, citing president of Mondelez's European division.
MDLZ

5
PRESS DIGEST- British Business - Sept 11

2018-09-11 reuters
Sept 11 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
ABF WPRXF GOOGL BABWF 87GO ICAGY GOOG MDLZ ASBFY ASBFF

2
Change Ahoy: Mondelez's new strategy weighs on earnings outlook

2018-09-07 reuters
CHICAGO (Reuters) - Mondelez International Inc (MDLZ.O) forecast smaller-than-expected earnings growth for 2019 as Chief Executive Dirk Van de Put unveiled a series of strategic changes, sending the Chips Ahoy-maker’s shares down 2.8 percent on Friday
MDLZ

2
UPDATE 1-Change Ahoy: Mondelez's new strategy weighs on earnings outlook

2018-09-07 reuters
CHICAGO, Sept 7 (Reuters) - Mondelez International Inc forecast smaller-than-expected earnings growth for 2019 as Chief Executive Dirk Van de Put unveiled a series of strategic changes, sending the Chips Ahoy-maker’s shares down 2.8 percent on Friday
MDLZ

2
Mondelēz International Outlines Long-Term Strategy and Provides 2019 Guidance

2018-09-07 globenewswire
BOSTON, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Today, at a meeting with analysts and investors in Boston, Mondelēz International Chief Executive Officer, Dirk Van de Put, and other senior executives outlined the company’s new long-term strategy to generate sustainable shareholder value. The company also established new long-term targets, reaffirmed its 2018 outlook, and provided an outlook for 2019.
MDLZ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 609207105